Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: A case-control study

BMC Medical Genetics

Volumn 10, Issue , 2009, Pages

  Lung, For Wey ^a,b,c,d   Shu, Bih Ching ^e   Kao, Wei Tsung ^a,f   Chen, C Nathan ^e,g   Ku, Yu Chi ^h   Tzeng, Dong Sheng ^a,b,c  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d Calo Psychiatric Centre   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f SHU TE UNIVERSITY   (Taiwan)

^g CNS Marketing   (Taiwan)

^h Beitou Armed Forces Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE; DOPAMINE 4 RECEPTOR; GUANOSINE; NEUROLEPTIC AGENT; PROTEIN P53; DRD4 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BEHAVIOR GENETICS; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTION; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT; VULNERABLE POPULATION; DNA SEQUENCE; GENETIC PREDISPOSITION; GENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE;

ADULT; CASE-CONTROL STUDIES; CODON; FEMALE; GENES, P53; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MINISATELLITE REPEATS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 74549205744     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-10-147     Document Type: Article

References (37)

1. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Katz M, Lohr J, Wu J, Lottenberg S, Jerabek PA, Trenary M, Tafalla R, Reynolds C, Bunney WE. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 1992, 49:935-942.
2. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992, 149:890-897.
3. Lewis DA, Lieberman JA. Catching up on schizophrenia: Natural history and neurobiology. Neuron 2000, 28:325-334. 10.1016/S0896-6273(00)00111-2, 11144342.
4. Benes FM, Walsh J, Bhattacharyya S, Sheth A, Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch Gen Psychiatry 2003, 60:359-364. 10.1001/archpsyc.60.4.359, 12695312.
5. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 2004, 161:109-115. 10.1176/appi.ajp.161.1.109, 14702258.
6. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jones EG. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995, 52:258-266.
7. Thune JJ, Uylings HB, Pakkenberg B. No deficit in total number of neurons in the prefrontal cortex in schizophrenics. J Psychiatr Res 2001, 35:15-21. 10.1016/S0022-3956(00)00043-1, 11287052.
8. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999, 45:17-25. 10.1016/S0006-3223(98)00281-9, 9894571.
9. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 2000, 48:641-650. 10.1016/S0006-3223(00)00988-4, 11032975.
10. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619. 10.1016/0092-8674(93)90509-O, 8358790.
11. Vekrellis K, McCarthy MJ, Watson A, Whitfield J, Rubin LL, Ham J. Bax promotes neuronal cell death and is downregulated during the development of the nervous system. Development 1997, 124:1239-1249.
12. Morrison RS, Kinoshita Y, Johnson MD, Guo W, Garden GA. p53-dependent cell death signaling in neurons. Neurochem Res 2003, 28:15-27. 10.1023/A:1021687810103, 12587660.
13. Lee DH, Kim C, Zhang L, Lee YJ. Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol 2008, 75:2020-2033. 10.1016/j.bcp.2008.02.023, 2424318, 18377871.
14. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997, 16:1391-1400. 10.1093/emboj/16.6.1391, 1169736, 9135154.
15. Majdan M, Lachance C, Gloster A, Aloyz R, Zeindler C, Bamji S, Bhakar A, Belliveau D, Fawcett J, Miller FD, Barker PA. Transgenic mice expressing the intracellular domain of the p75 neurotrophin receptor undergo neuronal apoptosis. J Neurosci 1997, 17:6988-6998.
16. Walker EF, Savoie T, Davis D. Neuromotor precursors of schizophrenia. Schizophr Bull 1994, 20:441-451.
17. Dumont P, Leu JIJ, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365. 10.1038/ng1093, 12567188.
18. Park JK, Lee HJ, Kim JW, Park YH, Lee SS, Chang HI, Song JY, Yoon DJ, Bahn GH, Shin YH, Kim YJ, Kim SA, Choe BK, Kim CJ, Chung JH. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophr Res 2004, 67:71-74. 10.1016/S0920-9964(03)00155-5, 14741326.
19. Lung FW, Lee TM, Shu BC, Chang FH. P53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004, 130:728-732. 10.1007/s00432-004-0605-4, 15365822.
20. Lin HY, Huang CH, Wu WJ, Chou YH, Fan PL, Lung FW. Mutation of the p53 tumor suppressor gene in transitional cell carcinoma of the urinary tract in Taiwan. Kaohsiung J Med Sci 2005, 21:57-64. 10.1016/S1607-551X(09)70278-5, 15825690.
21. Yang YC, Chang CL, Chen ML. Effect of p53 polymorphism on the susceptibility of cervical cancer. Gynecol Obstet Invest 2001, 51:197-201. 10.1159/000052924, 11306909.
22. Lung FW, Tzeng DS, Shu BC. Ethnic heterogeneity in allele variation in the DRD4 gene in schizophrenia. Schizophr Res 2002, 57:239-245. 10.1016/S0920-9964(01)00313-9, 12223255.
23. Tang Y, Wang Y, Cai Z. Schizophrenia and dopamine D4 gene polymorphism in Chinese population: association analysis. Zhonghua Yi Xue Za Zhi 2001, 81:995-998.
24. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995, 65:1157-1165.
25. Lung FW, Chen N, Shu BC. Dopamine D4 receptor gene (DRD4) and the -521C>T polymorphism of the upstream region of DRD4 gene in Schizophrenia. Psychiatr Genet 2006, 16:139-143. 10.1097/01.ypg.0000199446.54420.ff, 16829780.
26. Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog Brain Res 2008, 172:117-140. full_text, 18772030.
27. Porat S, Premkumar A, Simantov R. Dopamine induces phenotypic differentiation or apoptosis in a dose-dependent fashion: involvement of the dopamine transporter and p53. Dev Neurosci 2001, 23:432-440. 10.1159/000048730, 11872944.
28. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, Washington, DC, American Psychiatric Association, 4, American Psychiatric Association.
29. Beckmann H, Franzek E. The genetic heterogeneity of "schizophrenia". World J Biol Psychiatry 2000, 1:35-41. 10.3109/15622970009150564, 12607231.
30. Thibaut F. Schizophrenia: an example of complex genetic disease. World J Biol Psychiatry 2006, 7:194-197. 10.1080/15622970600994313, 17071540.
31. Catts VS, Catts SV. Apoptosis and schizophrenia: is the tumor suppressor gene, p53, a candidate susceptibility gene?. Schizophr Res 2000, 41:405-415. 10.1016/S0920-9964(99)00077-8, 10728718.
32. Chiu HJ, Wang YC, Chen JY, Hong CJ, Tsai SJ. Association study of the p53-gene Pro72Arg polymorphism in schizophrenia. Psychiatry Res 2001, 105:279-283. 10.1016/S0165-1781(01)00328-6, 11814547.
33. Ni X, Trakalo J, Valente J, Azevedo MH, Pato MT, Pato CN, Kennedy JL. Human p53 tumor suppressor gene (TP53) and schizophrenia: case-control and family studies. Neurosci Lett 2005, 388:173-178.
34. Yang Y, Xiao Z, Chen W, Sang H, Guan Y, Peng Y, Zhang D, Gu Z, Qian M, He G, Qin W, Li D, Gu N, He L. Tumor suppressor gene TP53 is genetically associated with schizophrenia in the Chinese population. Neurosci Lett 2004, 369:126-131. 10.1016/j.neulet.2004.07.068, 15450681.
35. Papiol S, Arias B, Barrantes-Vidal N, Guitart M, Salgado P, Catalan R, Fananas L. Analysis of polymorphisms at the tumor suppressor gene p53 (TP53) in contributing to the risk for schizophrenia and its associated neurocognitive deficits. Neurosci Lett 2004, 363:78-80. 10.1016/j.neulet.2004.03.049, 15158001.
36. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006, 81:47-53. 10.1016/j.schres.2005.08.014, 16226876.
37. Hall H, Lawyer G, Sillen A, Jonsson EG, Agartz I, Terenius L, Arnborg S. Potential genetic variants in schizophrenia: a Bayesian analysis. World J Biol Psychiatry 2007, 8:12-22. 10.1080/15622970600892004, 17366345.